Ectin Research AB operates as a pharmaceutical company. The firm develops a novel treatment that eliminates cancer tumors. Its drug candidate MFA-370, is under preclinical studies and aiming to treat metastatic bladder cancer, and other cancers such as breast, colorectal and prostate cancer cells. The company was founded by Christer Edlund, Marie-Lois Ivarsson, and Peter Falk on November 7, 2013 and is headquartered in Molndal, Sweden.